MARK MCDADE - 09 Jun 2022 Form 4 Insider Report for Talaris Therapeutics, Inc. (TRML)

Role
Director
Signature
/s/ Mary Kay Fenton, attorney-in-fact
Issuer symbol
TRML
Transactions as of
09 Jun 2022
Net transactions value
$0
Form type
4
Filing time
13 Jun 2022, 18:20:54 UTC
Previous filing
05 Apr 2022
Next filing
14 Jun 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TALS Stock Option (Right to Buy) Award $0 +14,501 $0.000000 14,501 09 Jun 2022 Common Stock 14,501 $8.45 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying this option shall vest as follows: the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting.